Figure 1. Pharmacokinetics and drug saturation in the NEON studies pharmacokinetics of davoceticept during monotherapy (NEON-1, solid lines) and pembrolizumab combination (NEON-2, dashed lines) by dose (●, 0.1 mg/kg davoceticept; ●, 0.3 mg/kg davoceticept) and regimen; once weekly, Q1W (A) and once every 3 weeks, Q3W (B); dose-dependent drug saturation in NEON-1 (C) and NEON-2 (D). Drug saturation of CD28 on circulating CD4+T cells by davoceticept was determined by flow cytometry pre-dose and following infusion using an antibody specific for davoceticept bound to CD28. Per cent saturation was calculated using a ratio of test article to saturated control and normalized to cycle 1 pre-dose.